The neurosteroid dhea as a marker for neuropathologies
CA 2398358 A1 · Owner: Papadopoulos, Vassilios · Inventors: Brown, Rachel C.; Cascio, Caterina; Papadopoulos, Vassilios
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
One of the major problems with the diagnosis and treatment of neurological diseases is the inability of clinicians to determine the onset of disease. The present invention describes methods and kits whereby the onset of neuropathology is detected by changes in the normal levels of neurosteroids and particularly DHEA and its metabolic precursors in the brain and serum.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed January 26, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended January 26, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by January 26, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.